Journal of the American College of Cardiology
Clinical ResearchClinical TrialBosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by Actelion Pharmaceuticals. Dr. Jaïs has received consulting fees, speaking fees, and honoraria from Actelion and GlaxoSmithKline. Dr. D'Armini has received consulting fees for service as a Steering Committee member for Actelion Pharmaceuticals. Dr. Jansa has received honoraria from Actelion Pharmaceuticals and fees for consultancies from Actelion, Pfizer, GlaxoSmithKline, and AOP Orphan Pharmaceuticals. Dr. Torbicki has received speaker fees and honoraria for consultations from Actelion, Bayer-Schering, and GlaxoSmithKline. Dr. Delcroix has received consulting fees and research grants from Actelion. Dr. Ghofrani has received honoraria from Actelion, Bayer, Encysive Pharmaceuticals, Ergonex, Pfizer, and GlaxoSmithKline. Dr. Hoeper has received speaker fees and honoraria for consultations from Actelion Pharmaceuticals, Encysive Pharmaceuticals, Pfizer, and Bayer-Schering. Dr. Lang has received honoraria from Actelion, Bayer-Schering, Pfizer, AstraZeneca, GlaxoSmithKline, AOP Orphan Pharmaceuticals, and Encysive Pharmaceuticals, and grant support from Actelion Pharmaceuticals, the EU, and the Austrian government. Dr. Mayer has received speaker fees from Actelion and Bayer. Dr. Pepke-Zaba has received honoraria from Actelion, Encysive Pharmaceuticals, Pfizer, GlaxoSmithKline, and Bayer-Schering, and also holds educational grants funded in part or whole from Actelion, Lung Rx, Pfizer, and Schering. Dr. Simonneau has received honoraria for consultations and/or lecture fees from Pfizer, GlaxoSmithKline, Actelion, Lilly, United Therapeutics, and Bayer, and industry sponsored grants from Pfizer, GlaxoSmithKline, Actelion, Lilly, and United Therapeutics. Dr. Rubin has received consulting fees for service as a Steering Committee member and advisor, and honoraria for lectures from Actelion. Dr. Perchenet and Adele Morganti are employees of Actelion Pharmaceuticals Ltd. Valerie V. McLaughlin, MD, served as Guest Editor for this article.